Abstract

The presence of Epstein-Barr virus in the tumor cells of nasopharyngeal carcinoma provides a potential therapeutic target. A number of possible approaches have emerged as a result of improved understanding of the biology of the virus. These approaches include adoptive immunotherapy with antigen-specific T cells, vaccines to induce antigen specific T-cell responses, pharmacologic or molecular therapies to alter expression of Epstein-Barr virus proteins in or alter malignant phenotype of tumor cells, or tissue specific expression of therapeutic genes.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.